Pfizer Inc. (PFE) — closed signal from October 9, 2025
Partial Published before the outcome was known, scored automatically when the window closed on January 7, 2026.
Predicted vs. what happened
What happened
Reached 42% of the predicted growth at its peak, without hitting the target.
The thesis — published October 9, 2025
Pfizer looks ready for a short-term bounce in healthcare. Analysts see stronger buying interest than usual and a trend that is starting to improve, with the recent average price edging up. This week, drug makers got a lift from U.S. tariff headlines, and a CDC meeting delay slightly reduced near-term policy noise. Over the next 0-3 months, we expect the price to drift back toward its typical range while watching pricing and the drug pipeline.
Primary drivers
- Buying interest looks strong and the recent average price trend is turning up
- U.S. tariff news recently helped drug companies, lifting the group higher
- Positive investor mood helps shares stay steady and build over time
- Healthcare is a safer area that can draw money when markets feel choppy
How it played out
PFE: the 12% target was not reached
On 2025-10-09, Lyra published a short-term Pfizer thesis at 25.37. It expected 12% growth toward 27.93 over the 2025-10-09 to 2026-01-07 window. The thesis pointed to stronger buying interest, an improving recent average price trend, U.S. tariff news that had helped drug companies, positive investor mood, and healthcare drawing money when markets felt choppy.
Inside the window, PFE rose, but not enough. The peak was 26.65 on 2025-12-15, a 5% gain. It never reached 27.93. By 2026-01-07, it ended at 25.28. The thesis partially played out, because the stock did rise, but it missed the published target.
What happened during the window
On 2025-12-16, MarketWatch reported that Pfizer revised its 2025 revenue outlook to 62 billion and gave 2026 revenue guidance of 59.5 billion to 62.5 billion. The article said the stock fell that day. This was reported during the measurement window, but it was not evidence of why the full-window move happened.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.